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Abstract: Drugs with low water solubility are predisposed to poor and variable oral 
bioavailability and, therefore, to variability in clinical response, that might be overcome 
through an appropriate formulation of the drug. Polymorphs (anhydrous and solvate/hydrate 
forms) may resolve these bioavailability problems, but they can be a challenge to ensure 
physicochemical stability for the entire shelf life of the drug product. Since clinical failures 
of polymorph drugs have not been uncommon, and some of them have been entirely 
unexpected, the Food and Drug Administration (FDA) and the International Conference on 
Harmonization (ICH) has required preliminary and exhaustive screening studies to identify 
and characterize all the polymorph crystal forms for each drug. In the past, the polymorphism 
of many drugs was detected fortuitously or through manual time consuming methods; 
today, drug crystal engineering, in particular, combinatorial chemistry and high-throughput 
screening, makes it possible to easily and exhaustively identify stable polymorphic and/or 
hydrate/dehydrate forms of poorly soluble drugs, in order to overcome bioavailability related 
problems or clinical failures. This review describes the concepts involved, provides examples 
of drugs characterized by poor solubility for which polymorphism has proven important, 
outlines the state-of-the-art technologies and discusses the pertinent regulations. 
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1. Introduction 
In the industrial development of a new drug substance and/or product, considerable problems are posed 
by candidate drugs with poor aqueous solubility, as this characteristic is related to poor bioavailability. 
Research and Development takes various approaches to enhancing the solubility and/or dissolution rate, 
and thus oral bioavailability, of poorly water-soluble drugs. One of the most common and effective 
approaches for increasing the solubility and dissolution rates of acidic and basic drugs is salt formation [1]. 
More recently, co-crystals, defined as crystalline materials comprised of at least two different components [2], 
have attracted attention for improving the dissolution rate of poorly water-soluble drugs [3]. Drug 
particle size reduction, affecting the dissolution rates, has been revealed one of oldest strategies for 
improving bioavailability of drugs and has been frequently applied in the pharmaceutical industry for 
routine production [4]. During the last years, the development of nanotechnologies have aroused the 
interest of researchers who have developed new technologies, easily industrially scalable, to reduce the 
particle size to nanodimensions [5,6]. Including or dispersing the poorly soluble drug in a carrier  
such as a cyclodextrin [7,8] or a polymer (solid dispersion) [9] are also common applied approaches. 
Modifications in the solid state, conversion from one polymorph to another [10], solvation/hydration [11], 
or amorphization [12,13] have been intentionally or unintentionally considered by the researchers and 
by the pharmaceutical industry during drug development of poorly-soluble drugs. 
When the polymorphic form modification approach is chosen, not only must the effective improvement 
of drug bioavailability—which is not always obvious—be verified, but problems with the drug substance 
and product stability can arise. Generally, metastable forms are more soluble than the corresponding 
stable polymorphic forms, but they transform to the more thermodynamically stable form in a relatively 
short time [14], and thus it is necessary to monitor the polymorphic transformation during formulation, 
manufacturing, and storage of dosage forms to ensure reproducible bioavailability after administration [15]. 
In addition, the change of the polymorphic form has frequently caused clinical failures once it is on 
the market. This review should provide a useful overview for pharmaceutical industry readers interested 
in the development of new drug substances and/or products using polymorphic modifications, and offers 
many examples of such efforts. 
Since the US Food and Drug Administration (FDA) and the International Conference on Harmonization 
(ICH) classify anhydrous, hydrate and solvate forms as polymorphs [16], in this review the term 
polymorphism will refer to both anhydrous and solvate (hydrate) forms. 
2. Importance of Solubility on the Bioavailability of Drugs 
Solubility is the ability of a solute to dissolve in a solvent to form a homogeneous solution of the 
solute in the solvent. This property is influenced by temperature and pressure [17]. Typical aqueous 
solubilities are indicated in several Pharmacopoeia, including the U.S. Pharmacopoeia (Table 1). 
Solubility is an essential property of drugs, because they must dissolve in order to be absorbed 
through membranes and reach the site of action. Consequently, solubility is one of the most critical and 
important parameters influencing drug bioavailability, that is, the ability of a drug to be available in an  
appropriate concentration at the site of action, independently of the pharmaceutical dosage form and 
route of administration. 
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Table 1. Aqueous solubilities according to the U.S. Pharmacopoeia. 
Freely Soluble 100–1000 mg/mL 
Soluble 33–100 mg/mL 
Sparingly soluble 10–33 mg/mL 
Slightly soluble 1–10 mg/mL 
Very slightly soluble 0.1–1 mg/mL 
Practically insoluble <0.1 mg/mL 
Poor aqueous solubility is the one of the major problems encountered during the development of new 
drug substances and/or drug products. This aspect becomes even more important if one considers that 
more than 40% of marketed immediate release oral drugs are practically insoluble (<100 g/mL) [18,19], 
and that fully 70% of new drug candidates in the pharmaceutical industry pipelines are practically 
insoluble in water [20]. Jean-Paul Garnier, CEO of GlaxoSmithKline, said that “About 50% of drug 
candidates that enter clinical trials fail due to efficacy and safety concerns, and the remaining 40% 
fizzle due to patent concerns and issues like solubility and drug interaction” [21]. 
To have an idea of the importance of drug solubility and how poor aqueous solubility limits drug 
bioavailability, one can refer to some examples offered by Amidon et al., [22] concerning the volumes 
needed to dissolve poorly water soluble drugs according to their dose. Some of the consequences of 
the inadequate aqueous solubility of a drug are limited and variable absorption, formulation and food 
effects, and poor tissue distribution and metabolism [23]. 
The importance of the solubility parameter is confirmed in the Biopharmaceutical Classification System 
(BCS) [24], a scientific framework for classifying drug substances based on their aqueous solubility 
and intestinal permeability [22,25]. The BCS takes into account three major factors that govern the rate and 
extent of drug absorption from immediate release solid oral dosage forms: (1) dissolution; (2) solubility; 
and (3) intestinal permeability. According to the BCS, drug substances are classified as follows: 
Class 1: High Solubility–High Permeability 
Class 2: Low Solubility–High Permeability 
Class 3: High Solubility–Low Permeability 
Class 4: Low Solubility–Low Permeability 
3. The Polymorphism of Drugs: Anhydrous and Solvated Forms 
Among the various techniques used to enhance the solubility of poorly soluble drugs are physical and 
chemical modifications of the drug, and methods such as particle size reduction, salt formation, solid 
dispersion, use of surfactant, and complexation [23]. Selection of a solubility improving method depends 
on drug property, site of absorption, and required dosage form characteristics [26]. 
Crystalline polymorphs have the same chemical composition, but different internal crystal structures, 
and therefore possess different physicochemical properties [27] because of their different lattice structures 
and/or different molecular conformations [28]. The phenomenon of polymorphism is quite common 
among organic molecules, and many drugs can crystallize into different polymorphic forms [29–32]. 
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Polymorphic forms of drugs can prove interesting for drug developers because their thermodynamic and 
physicochemical properties, such as energy, melting point, density, stability, and in particular solubility, 
may offer an improvement on the original form. 
Generally, the solubility of metastable polymorphs is kinetically higher than that of a thermodynamically 
more stable polymorph [33], offering, at least in theory, a solution to bioavailability problems. 
Actually, it has been demonstrated that differences between the solubility of one polymorph and 
another are typically lower than a factor of 2 [34] or more rarely of 5 [35]. Thus, while a polymorph may 
offer a slight improvement in solubility compared to the original compound, this benefit may be offset 
the fact that it is also less stable than the original, and thus there may be no advantage in choosing this 
polymorph over the original compound. Actually, metastable and more soluble forms tend to convert into 
the more thermodynamic stable form in a relatively short time. The presence of specific excipients, or 
particular chemical and/or technological processes may accelerate the transition to the solid state [36,37]. 
This transition may proceed according to the relative thermodynamic stability of metastable forms, or 
be accelerated by the presence of seeds of one polymorph in another, with important repercussions on 
clinical practice, as it was the case of ritonavir (refer to the specific paragraph). 
Solvates, also inappropriately termed pseudopolymorphs [38], are crystalline solids containing 
within the crystal structure either stoichiometric or nonstoichiometric proportions of solvent. When the 
incorporated solvent is water, the solvate is called a hydrate [27]. In general, it is undesirable to use solvates 
for drugs and pharmaceuticals, as the presence of organic solvent residues may be toxic; regulations for 
all the organic solvents in products for human use establish specific limits to how much daily exposure 
to residual solvent in the formulated preparation is allowed. 
The solubility and dissolution rate of a drug can significantly differ for different solvates, and in 
particular hydrates. Important reviews concerning pharmaceutical solvates and hydrates are those of 
Morris [39] and Khankari and Grant [11]. 
Hydrates may have a faster or slower dissolution rate than the corresponding anhydrous form, though 
more frequently, the former are slower than the latter [40], perhaps because there are fewer sites of the 
drug molecule available for interaction with water during dissolution. A classic example is theophylline 
anhydrate, which dissolves faster than its hydrate form [41,42]. 
In other cases, the hydrate form exhibits a more rapid dissolution rate than its anhydrous form: for 
example, erythromycin dihydrate was found to exhibit a significantly faster dissolution rate than that 
of monohydrate and anhydrous forms [43,44]. 
Glibenclamide has been isolated as pentanol and toluene solvates, and these solvates exhibited higher 
solubility and dissolution rate than two non-solvated polymorphs [45]. 
The physical stability of hydrates and anhydrous forms strongly depends upon the relative humidity 
and/or temperature of the environment [46–48], and transitions from one form to the other occur as a 
consequence of variations in storage conditions and/or technological treatments [37,49]. 
In particular, anhydrous to hydrate transitions can occur during dissolution at the drug/medium 
interface and can affect dissolution rate and perhaps bioavailability [46]. 
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4. Polymorph Screening 
The polymorph screening process seeks to determine whether a given compound exists in polymorphic 
forms [50]. In recent decades, several techniques have been developed to improve the polymorph screening 
of drugs. 
The concept of crystal engineering was introduced by Pepinsky in 1955 [51] and first applied by 
Schmidt in the context of covalent bond formation in the solid state [52]. It is traditionally defined as 
the deliberate design and control of molecular packing within a crystal structure with the intention of 
generating a solid that shows a particular desirable characteristic [53–55]. Combinatorial chemistry and 
high-throughput screening used in drug discovery have resulted in an increase of poorly water soluble 
drug candidates [56,57]. 
Among traditional methods to generate polymorphs (as well as hydrates and solvates), manual 
techniques [58] are time and material consuming, and sometimes fail to identify all possible polymorphs 
for a compound. 
The development of computer software tools that consider the arrangement of atoms within a compound 
to predict the possible crystal structures has been a boon to the pharmaceutical industryenabling savings of 
time and materials in the process of identifying the most thermodynamically stable polymorph, and 
making it possible to tailor the manufacturing process for production of the active ingredient [59]. 
High-throughput polymorphism screening has been developed with the aim of accelerating the 
identification of potential polymorphs for a drug, and thus avoid problems during drug development [60,61]. 
The efficiency of screening in HT mode is estimated to be about two orders of magnitude greater than 
that of traditional bench-scale approaches [62], and it has been applied to numerous drugs. 
A high-throughput (HT) crystallization study of an experimental angiotensin II antagonist and sertraline 
hydrochloride identified new forms, improved understanding of the transitions among different forms, 
and demonstrated that an HT strategy coupled with critical analysis can be used to rank the usefulness 
of crystal forms [62]. 
Ritonavir is a drug that has been used to treat HIV-1 infections since 1996. In 1998, a new metastable 
and unknown form posed major bioavailability problems. Afterwards, HT screening identified a total 
of five forms, the two well-known forms and three unknown ones [60]. 
A high-throughput co-crystal slurry screening study of indomethacin that used in situ Raman 
microscope and a multi-well plate not only provided information about co-crystal formation within one 
day, but also yielded data about the equilibrium of co-crystal formation and polymorphic transformation 
in just one screening [63]. 
5. Case Studies of Polymorphic Drugs 
The following paragraphs report several examples of poorly soluble drugs for which polymorphic 
issues proved important. A summary is given in Table 2. 
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Table 2. Summarization of polymorphism of several drugs. 
Drug Substance Polymorphism Aspects Bioavailability Issues 
Chloramphenicol palmitate 
 
Chloramphenicol palmitate is a prodrug of chloramphenicol with antibiotic properties [64]. 
Chloramphenicol palmitate exist in three polymorphic forms: (A, B, C) [65,66],  
the stable form A (biologically inactive modification), the metastable form B  
(active modification) and unstable form C [67–69].  
The three crystalline forms were also called α, β and γ. The α form is unstable at room 
temperature and gradually transforms to β on storage [70,71]. 
Form B (β) dissolves faster than Form A (α), and has a much higher solubility [72–74].  
Low serum levels for the stable polymorph A were observed [75]. 
Oxytetracycline 
 
Oxytetracycline is a broad spectrum antibiotic.  
It exists in two different polymorphs [76]. 
Oxytetracycline showed differences in patients’ blood levels [77] or differences in in vitro 
dissolution of tablets [78] because of differences in polymorphic forms. 
Carbamazepine 
 
Carbamazepine is used in the treatment of epilepsy and trigeminal neuralgia.  
Different polymorphic forms were described [79–91]. Four anhydrous polymorphs were 
characterized: I, II, III, and IV, respectively identified as triclinic, trigonal, monoclinic, and 
monoclinic [77]. 
In spite different studies demonstrated similar pharmacokinetics in humans of anhydrous and 
dihydrate forms of carbamazepine [92] and no differences in bioavailability between a 
generic carbamazepine product and an innovator product [93], several clinical failures were 
reported concerning carbamazepine [94,95], in particular with generic carbamazepine  
tablets [96]. More recently, it was confirmed that the initial dissolution rate of carbamazepine 
was in the order of form III > form I > dihydrate, while the order of AUC values was form  
I > form III > dihydrate. This discrepancy may be attributed to the rapid transformation from 
form III to dihydrate in GI fluids [97]. 
Ritonavir 
 
Ritonavir is an antiretroviral drug belonging to protease inhibitor class and used to treat 
HIV-1 infection.  
Ritonavir exhibits conformational polymorphism [98] and a total of five forms were 
described [60]. The forms I and II were more extensively characterized [98]. 
2 years after the launch of the first ritonavir product, several batches failed dissolution 
specifications because the presence of a different polymorphic form having ~50% lower 
intrinsic solubility of reference form [36].  
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Table 2. Cont. 
Drug Substance Polymorphism Aspects Bioavailability Issues 
Atorvastatin calcium 
 
Atorvastatin calcium is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A  
(HMG-CoA) reductase, with strong ability to lowering blood cholesterol.  
At least 60 polymorphic forms/solvates/hydrates have been patented [99–101].  
It is not unusual to verify the presence of polymorphic impurities in the marketed 
atorvastatin calcium (API) with consequences on drug bioavailability and stability [102]. 
Atorvastatin is unstable and the hydroxy acid form is converted to lactone form that is  
15 times less soluble than the hydroxyl acid form [103,104]. 
This instability of atorvastatin calcium leading to poor solubility (0.1 mg/mL) is the main 
cause for low bioavailability of the drug after oral administration as the absolute 
bioavailability of atorvastatin calcium is only 14% [105].  
Axitinib 
 
Axitinib is a tyrosine kinase inhibitor of endothelial growth factor interrupting tumor 
angiogenesis and thus, preventing the growth of cancer cells.  
60 solvates, polymorphs of solvates, and five anhydrous forms were  
discovered [106–109].  
The commercial formulation under trade name Inlyta® contains the stable anhydrous  
form [107].  
Phanylbutazone 
 
Phenylbutazone is a potent anti-rheumatic drug existing in different polymorphic and 
solvated forms [110–113]. 
Anhydrous forms I and II were more extensively described and form II resulted more 
soluble than form I. The Form III is a highly unstable form [110]. 
Anhydrous forms I and II polymorphic forms exhibited different solubilities, dissolution 
rates and oral absorption [110,114].  
Rifaximin 
 
Rifaximin is a synthetic derivative of rifamycin, with very low gastrointestinal 
absorption, but still displaying a broad spectrum of antibacterial activity [115–117].  
Rifaximin shows crystal polymorphism (poolymorphs α, β, γ, δ, ε) [118,119]. The 
polymorph α is the most thermodynamically stable form and the commercial one.  
In vitro studies show different dissolution and solubility rates for these polymorphs, and  
in vivo investigations in dogs found different pharmacokinetic patterns, with δ and γ 
polymorphs displaying the highest systemic bioavailability [119].  
The most PK parameters were significantly higher after administration of generic  
rifaximin, because of the presence of both rifaximin-α and amorphous  
forms [120]. 
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5.1. Chloramphenicol Palmitate 
A decades-old classic example of the importance of polymorphism to bioavailability is chloramphenicol 
palmitate, a prodrug of chloramphenicol with antibiotic properties, developed with the objective of 
obtaining a more pleasant flavored derivative [64]. Chloramphenicol palmitate exists in three polymorphic 
forms [65,66,70,71], the stable form A (biologically inactive modification), the metastable form B 
(active modification) and the unstable form C [67], which recently have been fully characterized 
thanks to advances in analytical methods [68,69]. Polymorph A is the thermodynamically stable one, 
but its absorption in humans is significantly lower than that of polymorph B [72], because Form B 
dissolves faster than Form A, and has much higher solubility [73]. This solubility difference probably 
results in the difference in ester hydrolysis rates, and thus in the difference in oral absorption, if one 
considers that chloramphenicol palmitate must be hydrolyzed by intestinal esterases before it can be 
absorbed [74]. These results were also proven by the low serum levels reached by the stable polymorph 
A, whereas the metastable polymorph yielded much higher serum levels when the same dose was 
administered [75]. 
5.2. Oxytetracycline 
While for many years it has been known from various studies that patient blood levels of 
oxytetracycline differed according to the supplier of the oxytetracycline capsules, [77] or that in vitro 
dissolution performance of oxytetracycline tablets differed according to the various sources [78], only 
more recently have these differences been attributed to the presence of different polymorphs [76]. 
Tablets prepared from the form A polymorph dissolved significantly more slowly than tablets prepared 
from polymorph B: indeed, the tablets with form A polymorph exhibited about 55% dissolution at 30 min, 
while the tablets with form B polymorph exhibited almost complete (95%) dissolution at the same time. 
Further studies characterizing the physical and chemical properties of oxytetracycline polymorphs would 
be useful, as no recent works are available in the literature. 
5.3. Carbamazepine 
Highly different polymorphic forms of carbamazepine, a drug used in the treatment of epilepsy and 
trigeminal neuralgia, were discovered through classical crystallization methods and fully characterized 
from a physicochemical point of view [79–89]. More recently, a crystal engineering design strategy has 
facilitated supramolecular synthesis of 13 new crystalline phases of carbamazepine [90]. 
Even though different studies demonstrated that anhydrous and dihydrate forms of carbamazepine 
have similar pharmacokinetics in humans [92], and another indicated that there are no differences in 
bioavailability between a generic carbamazepine product and an innovator product [93], several clinical 
failures with carbamazepine were reported [94,95]. In particular, several problems were observed with 
Generic carbamazepine tablets, which were recalled due to clinical failures and dissolution changes [96]. 
It was suggested that discrepancies in clinical parameters and irreproducible clinical behavior within 
different batches and suppliers of the generic carbamazepine tablets were due to moisture uptake during 
storage. Actually, it is well known that anhydrous carbamazepine converts to the dihydrate within 1 h, 
when the anhydrous form is suspended in water [91]. More recently, it was confirmed that the initial 
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dissolution rate of carbamazepine was in the order of form III > form I > dihydrate, while the order of 
AUC values was form I > form III > dihydrate. This discrepancy may be attributed to the rapid 
transformation from form III to dihydrate in GI fluids [97]. 
5.4. Ritonavir 
Ritonavir, an antiretroviral drug of the protease inhibitor class used to treat HIV-1 infections, was 
found to have polymorphism that strongly impacts on solubility and dissolution rate. Originally, only 
one form was described, and was formulated as soft gel capsules containing an ethanol/water solution 
molecule. Two years after the launch of the product, several batches failed dissolution specifications.  
A new thermodynamically stable Form II was discovered, but this form precipitated out of solution, 
having ~50% lower intrinsic solubility than the reference form. This finally forced the manufacturer to 
recall the original formulation from the market [36] and reformulate it in an oily vehicle. 
Using solid state spectroscopy and microscopy techniques including solid state NMR, Near Infrared 
Spectroscopy, powder X-ray Diffraction and Single crystal X-ray, ritonavir was found to exhibit 
conformational polymorphism with two unique crystal lattices that have significantly different solubility 
properties [98]. In addition, HT screening identified a total of five forms, the two well know forms and 
three unknown ones [60]. 
5.5. Atorvastatin Calcium 
Atorvastatin calcium is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, with strong ability to lower blood cholesterol. Atorvastatin, the most preferred molecule 
among statins, was developed and marketed by Pfizer under the trade name Lipitor® [121] and was the 
number one selling drug in the US until its patent expired in 2011. Atorvastatin is unstable and the 
hydroxyacid form (HF) is converted to a lactone form (LF), which is 15 times less soluble than the 
hydroxyacid form [103,104]. This instability of atorvastatin calcium leading to poor solubility (0.1 mg/mL) 
is the main cause for low bioavailability of the drug after oral administration: the absolute bioavailability 
of ATC is only 14% [105].  
At least 60 polymorphic forms/solvates/hydrates have been patented [99–101] and several 
pharmaceutical companies are developing or have developed generic drug formulations based on 
different atorvastatin calcium polymorphs. 
Due to the patent expiration, several companies produce the active pharmaceutical ingredient (API) 
of atorvastatin calcium, available on the market as stable crystalline polymorph I or amorphous form. 
It was not unusual to verify the presence of polymorphic impurities in the marketed atorvastatin calcium 
(API) with consequences on drug bioavailability and stability [102]. 
5.6. Axitinib 
Axitinib is a tyrosine kinase inhibitor of endothelial growth factor that interrupts tumor angiogenesis 
and thus prevents the growth of cancer cells. Because of its strong molecular flexibility, 60 solvates, 
polymorphs of solvates, and five anhydrous forms have been discovered [106–109]. The commercial 
formulation under trade name Inlyta® contains the stable anhydrous form. Unusually, conventional 
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crystallization methods did not lead to the discovery of this most stable polymorph; rather, it was 
obtained by the uncommon method of slurrying the solvates at high temperature. Understanding of the 
desolvation pathway was critical for obtaining the most stable polymorph of axitinib [107]. 
5.7. Phenylbutazone 
Phenylbutazone is a potent anti-rheumatic drug that exists in different polymorphic [110–112] and 
solvated forms [113]. Different solubilities, dissolution rates and oral absorption were highlighted 
between two different polymorphic forms [114]. 
5.8. Rifaximin 
Rifaximin is a synthetic derivative of rifamycin with very low gastrointestinal absorption, but that 
nonetheless displays a broad spectrum of antibacterial activity [115–117]. According to the European 
Pharmacopoeia, rifaximin shows crystal polymorphism [118] and several polymorphs (α, β, γ, δ, ε) 
have been described [119]. The most thermodynamically stable form, polymorph α, is the one used 
commercially. In vitro studies show different dissolution and solubility rates for these polymorphs, and 
in vivo investigations in dogs found different pharmacokinetic patterns, with δ and γ polymorphs 
displaying the highest systemic bioavailability [119]. Blandizzi et al., [120] compared one generic 
rifaximin formulation with the branded product (the latter containing only polymorph-α) and found 
that most PK parameters such as highest concentration achieved in plasma (Cmax), area under the 
concentration-time curve (AUC), and cumulative urinary excretion were significantly higher after 
administration of generic rifaximin. X-ray power diffraction analysis of the generic formulation showed 
the presence of both rifaximin-α and amorphous rifaximin, which could have contributed to the increased 
systemic bioavailability of the generic formulation. 
6. Regulatory Considerations 
For approval of a new drug, the drug substance guideline of the US Food and Drug Administration 
(FDA) states that “appropriate” analytical procedures need to be used to detect polymorphs, hydrates 
and amorphous forms of the drug substance and also stresses the importance of controlling the crystal 
form of the drug substance during the various stages of product development [122]. 
Modern techniques such as ss-NMR and NIR can identify polymorphs in dosage forms (within 
limits), and should help improve mechanistic understanding of polymorphs in future studies [123]. Fast 
and easily applicable techniques such as DSC can determine the solubility of different polymorphs very 
rapidly and accurately [124]. The selection of crystal forms of improved solubility and bioavailability is 
possible when appropriate strategies are applied to guarantee the drug stability over the shelf life of the 
drug product. The evaluation of crystal transitions through appropriate analytical technologies serves 
to predict unwanted conversions during the drug product shelf life. 
7. Conclusions 
The possibility of detecting drug polymorphism can be viewed in two opposite ways: as a risk of 
clinical failure when an undesired solid state conversion occurs, or as an advantage when more soluble 
Molecules 2015, 20 18769 
 
 
polymorphs may be selected to overcome bioavailability problems. Thus, the pharmaceutical industry 
must carefully evaluate the presence of the phenomenon of the polymorphism for every drugs under 
development. In the past, when analytical techniques were not sophisticated enough to adequately detect 
polymorphism of drugs under development, several clinical failures emerged during the marketing 
phases, in some cases with serious repercussions for the pharmaceutical industry, such as the obligation 
to withdraw or reformulate the product. Now, the use of state-of-the-art technologies makes it possible 
to prevent this risk and to better and fully investigate the existence of different polymorphic forms of 
drugs in the industrial pipeline. In recent years, regulatory organisms such as the FDA and ICH have 
pressed the pharmaceutical industry to adopt methodologies and innovative analytical techniques that 
should provide better understanding of the polymorphism phenomenon for every drug under development, 
and enable Quality Control Departments to adequately evaluate the solid state of batches produced. 
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